Results 21 to 30 of about 1,320,066 (287)
Proton Pump Inhibitors and CKD [PDF]
Journal of the American Society of Nephrology, 2016 Proton pump inhibitors (PPIs) are taken by millions of people around the world, often for many months or even years, and some take PPIs on a permanent basis. PPIs, which are available both by prescription and over the counter, generally have an excellent overall safety profile.
Dennis G, Moledina, Mark A, Perazella
openaire +2 more sources
Pharmacology of proton pump inhibitors [PDF]
Current Gastroenterology Reports, 2008 The gastric H,K-ATPase is the primary target for the treatment of acid-related diseases. Proton pump inhibitors (PPIs) are weak bases composed of two moieties, a substituted pyridine with a primary pK(a) of about 4.0, which allows selective accumulation in the secretory canaliculus of the parietal cell, and a benzimidazole with a second pK(a) of about ...
Jai Moo, Shin, George, Sachs
openaire +2 more sources
ENDOSCOPIC AND HISTOPATHOLOGIC GASTRIC CHANGES IN CHRONIC USERS OF PROTON-PUMP INHIBITORS
Arquivos de Gastroenterologia, 2015 Background Proton-pump inhibitors have been used for at least two decades. They are among the most commonly sold drugs in the world. However, some controversy remains about the indications for their use and the consequences of their prolonged use ...
Sílvia Maria Perrone CAMILO +5 more
doaj +1 more source
Proton Pump Inhibitors and Clopidogrel [PDF]
Cardiovascular Therapeutics, 2010 Proton pump inhibitors are often prescribed for patients on clopidogrel to prevent gastrointestinal bleeding complications. Recent data suggest higher rates of adverse cardiovascular events in patients on proton pump inhibitors and clopidogrel, in comparison to patients on clopidogrel only.
Michael A, Gaglia, Ron, Waksman
openaire +2 more sources
PLoS ONE, 2019 Stroke patients are at high risk of developing pneumonia, which is major cause of post-stroke mortality. Proton pump inhibitors and H2 receptor antagonists are anti-ulcer drugs, which may predispose to the development of pneumonia by suppression of the ...
Tae-Jin Song, Jinkwon Kim
doaj +1 more source
Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin [PDF]
, 2010 Harald Vonkeman, Inger Meek, Mart van de LaarDepartment of Rheumatology and Clinical Immunology, Arthritis Centre Twente, Medisch Spectrum Twente and University of Twente, Enschede, The NetherlandsAbstract: Low-dose aspirin is widely used in the primary ...
Vonkeman, Harald +5 more
core +2 more sources
Clopidogrel and proton pump inhibitors [PDF]
Canadian Medical Association Journal, 2014 The points raised by Juurlink[1][1] in response to our article[2][2] are worthy of consideration. The release kinetics of the drugs as given in the COGENT trial may have attenuated the potential for a drug–drug interaction.
openaire +5 more sources
The impact of drug-drug interactions between proton pump inhibitors and metformin: A systematic review of clinical evidence [PDF]
PharmaciaMetformin, a substrate of the organic cation transporters, is commonly co-prescribed with proton pump inhibitors, which inhibits these transporters. However, the clinical significance of this potential drug-drug interaction remains unclear.
Ria Andani Antong +3 more
doaj +3 more sources
Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors
eJHaem, 2020 Background Iron deficiency anemia without evidence for blood loss can present a diagnostic challenge. Proton pump inhibitors have been associated with iron deficiency anemia for many years, yet the relationship between the two until recently was not ...
Michael Boxer
doaj +1 more source
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry [PDF]
, 2015 Emerging viral diseases pose a threat to the global population as intervention strategies are mainly limited to basic containment due to the lack of efficacious and approved vaccines and antiviral drugs.
Temperton, Nigel J. +24 more
core +1 more source